Clinical Trial

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-15
Trial Details
NCT Number NCT07425392
Lead Sponsor Vaxcyte, Inc.
Conditions Pneumococcal Vaccines
Enrollment 752 participants
Start Date 2026-02-09
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-30